Quanterix Co. (NASDAQ:QTRX - Get Free Report) Director David R. Walt bought 131,869 shares of Quanterix stock in a transaction on Friday, June 6th. The shares were purchased at an average cost of $5.43 per share, for a total transaction of $716,048.67. Following the completion of the purchase, the director now directly owns 1,628,802 shares of the company's stock, valued at $8,844,394.86. This trade represents a 8.81% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link.
Quanterix Trading Down 7.1%
Shares of NASDAQ:QTRX traded down $0.47 during trading on Thursday, hitting $6.19. 730,843 shares of the stock were exchanged, compared to its average volume of 591,546. The company has a market cap of $240.35 million, a PE ratio of -5.84 and a beta of 1.05. The company has a fifty day moving average price of $5.32 and a two-hundred day moving average price of $7.81. Quanterix Co. has a 12-month low of $4.05 and a 12-month high of $18.02.
Quanterix (NASDAQ:QTRX - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.16. The firm had revenue of $30.33 million during the quarter, compared to the consensus estimate of $28.27 million. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. Equities research analysts anticipate that Quanterix Co. will post -0.98 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
QTRX has been the topic of several research reports. Leerink Partnrs lowered shares of Quanterix from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. Canaccord Genuity Group reduced their target price on shares of Quanterix from $15.00 to $12.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Leerink Partners reissued a "market perform" rating and issued a $8.00 price target (down previously from $12.00) on shares of Quanterix in a research report on Wednesday, April 30th. Scotiabank restated an "outperform" rating on shares of Quanterix in a research note on Tuesday, March 25th. Finally, Wall Street Zen cut Quanterix from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $15.60.
View Our Latest Stock Report on QTRX
Institutional Trading of Quanterix
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Ameriprise Financial Inc. raised its stake in Quanterix by 111.3% in the 4th quarter. Ameriprise Financial Inc. now owns 3,205,928 shares of the company's stock valued at $34,079,000 after purchasing an additional 1,688,680 shares during the last quarter. William Blair Investment Management LLC acquired a new position in shares of Quanterix in the fourth quarter valued at approximately $11,290,000. Invenomic Capital Management LP acquired a new position in shares of Quanterix in the first quarter valued at approximately $5,872,000. Trium Capital LLP purchased a new position in shares of Quanterix during the first quarter valued at approximately $3,642,000. Finally, Nuveen LLC acquired a new stake in Quanterix during the first quarter worth approximately $2,704,000. 86.48% of the stock is currently owned by hedge funds and other institutional investors.
About Quanterix
(
Get Free Report)
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.
Featured Stories
Before you consider Quanterix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quanterix wasn't on the list.
While Quanterix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
